论文信息 - Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study - 字舞流文

Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

P. Gibbs | D. Doval | T. Yau | R. Lim | K. Yeh | A. Cheng | L. Shen | B. Ma | T. Price | I. Chung | Jen‐Kou Lin | Z. Guan | A. Hill | V. Srimuninnimit | F. Beier | N. Masood | Atul Sharma | K. Suh | Tsai-Sheng Yang | Xiuwen Wang | B. Shim | E. Sirachainan | G. Dai | G. Cornelio | S. Oh | Adel M Zaatar | Hwei‐Ming Wang | C. Gorospe | S. Chatterjee | Tsai‐Sheng Yang